CurveBeam AI Accelerates Growth with China JV and $6.5m Capital Raise

Strong Sales Momentum in Q1 FY26

CurveBeam AI has kicked off FY26 with encouraging commercial traction, reporting purchase orders for four devices in the first quarter, including three HiRise™ units. This represents a 33.3% increase over the same period last year, underscoring growing demand for the company’s weight-bearing CT imaging technology in the US market. While revenue recognition may lag due to installation and training timelines, these purchase orders are a key indicator of sales momentum.

Strategic Capital Raise and Vendor Financing

The company successfully completed a placement raising A$6.5 million from institutional and sophisticated investors at 40.5 cents per share, a move that strengthens its balance sheet with limited dilution. Additionally, CurveBeam AI has signed an agreement for a vendor financing facility worth approximately A$18 million, which should provide flexible funding to support sales growth and operational needs.

China Market Entry via Joint Venture

A major highlight of the quarter is the execution of final contracts with Weiying Intelligent Medical Technology (WIMT), a joint venture partner linked to Wego Orthopedics. This deal grants WIMT exclusive rights to distribute US-manufactured CurveBeam products in China and to locally manufacture and sell the company’s WBCT devices under a royalty model. The JV includes upfront and milestone-based investments totaling up to A$10 million, signaling a significant commitment to penetrate one of the world’s largest and fastest-growing medical device markets.

Local manufacturing in China is expected to reduce costs, improve margins, and mitigate supply chain risks, especially those related to tariffs and logistics. The dual-factory strategy, with production in both the US and China, positions CurveBeam AI to better navigate global market complexities and regulatory requirements.

Progress on Product Validation and Regulatory Milestones

CurveBeam AI continues to advance the validation of its enhanced HiRise™ system with a major robotic surgery vendor, including recent system demonstrations. While the timeline for completion remains uncertain due to the vendor’s internal processes, the company remains optimistic about meeting the necessary requirements for labeling updates.

On the regulatory front, the company targets mid-2026 for FDA clearance of its bone mineral density (BMD) software module designed for multidetector CT scanners. This milestone is critical as it opens the door to SaaS-based revenue streams in acute care settings, leveraging existing CT infrastructure for rapid BMD assessment.

Competitive Landscape and Future Outlook

CurveBeam AI maintains a competitive edge in the weight-bearing CT imaging space, with proprietary AI technology and a focus on bilateral, natural weight-bearing scans. Competitors like PlanMed and Canon offer alternative solutions but face limitations in accessibility and automation. The company’s strategic moves in China and its financing initiatives position it well for accelerated innovation and expanded global reach.